<?xml version="1.0" encoding="utf-8" ?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN"
                  "JATS-publishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.2" article-type="other">
<front>
<journal-meta>
<journal-id></journal-id>
<journal-title-group>
<journal-title>Journal of Open Source Software</journal-title>
<abbrev-journal-title>JOSS</abbrev-journal-title>
</journal-title-group>
<issn publication-format="electronic">2475-9066</issn>
<publisher>
<publisher-name>Open Journals</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">2706</article-id>
<article-id pub-id-type="doi">10.21105/joss.02706</article-id>
<title-group>
<article-title>c212: An R Package for the Detection of Safety Signals in
Clinical Trials Using Body-Systems (System Organ
Classes)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-0120-625X</contrib-id>
<string-name>Raymond Carragher</string-name>
<xref ref-type="aff" rid="aff-1"/>
<xref ref-type="aff" rid="aff-2"/>
<xref ref-type="aff" rid="aff-4"/>
</contrib>
<contrib contrib-type="author">
<string-name>Chris Robertson</string-name>
<xref ref-type="aff" rid="aff-2"/>
<xref ref-type="aff" rid="aff-3"/>
</contrib>
<aff id="aff-1">
<institution-wrap>
<institution>Strathclyde Institute of Pharmacy and Biomedical Sciences,
University of Strathclyde, Glasgow, UK</institution>
</institution-wrap>
</aff>
<aff id="aff-2">
<institution-wrap>
<institution>Department of Mathematics and Statistics, University of
Strathclyde, Glasgow, UK</institution>
</institution-wrap>
</aff>
<aff id="aff-3">
<institution-wrap>
<institution>Health Protection Scotland, NHS National Services Scotland,
Glasgow, UK</institution>
</institution-wrap>
</aff>
<aff id="aff-4">
<institution-wrap>
<institution>Health Data Research (UK), University of Strathclyde,
Glasgow, UK</institution>
</institution-wrap>
</aff>
</contrib-group>
<volume>5</volume>
<issue>56</issue>
<fpage>2706</fpage>
<permissions>
<copyright-statement>Authors of papers retain copyright and release the
work under a Creative Commons Attribution 4.0 International License (CC
BY 4.0)</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>The article authors</copyright-holder>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>Authors of papers retain copyright and release the work under
a Creative Commons Attribution 4.0 International License (CC BY
4.0)</license-p>
</license>
</permissions>
<kwd-group kwd-group-type="author">
<kwd>Adverse event</kwd>
<kwd>Safety</kwd>
<kwd>Pharmacovigilance</kwd>
<kwd>Clinical trials</kwd>
<kwd>False Discovery Rate</kwd>
<kwd>Body-systems</kwd>
<kwd>System organ classes</kwd>
<kwd>Bayesian hierarchy</kwd>
<kwd>Multiple comparisons.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="summary">
  <title>Summary</title>
  <p>Safety in clinical trials may be characterised by the incidence or
  occurrence of adverse events. The statistical analysis of this data is
  complicated by the large number of adverse events recorded, with low
  event rates, small effect sizes and low power all contributing to the
  difficulty in determining a robust safety profile for a treatment
  during the trial process.</p>
  <p>In addition to end of trial analyses, a number of interim analyses
  may take place at different time points during the trial lifecycle.
  These offer the additional statistical challenge of testing
  accumulating data, with possibly differing recruitment rates on trial
  arms contributing to a lack of balance in the data.</p>
  <p>Adverse events are typically defined by medical dictionaries, which
  provide a common reference terminology for use in and between clinical
  trials. There are a number of medical dictionaries in current use, all
  of which provide similar services. One such dictionary is
  <ext-link ext-link-type="uri" xlink:href="http://www.meddra.org/">MedDRA</ext-link>
  (Medical Dictionary for Regulatory Activities), which was developed by
  the
  <ext-link ext-link-type="uri" xlink:href="http://www.ich.org/">ICH</ext-link>
  (International Council for Harmonisation of Technical Requirements for
  Pharmaceuticals for Human Use) and is widely used by regulatory
  bodies, clinical research organisations (CROs), and pharmaceutical
  companies. WHO-ART (World Health Organisation Adverse Reaction
  Terminology) is a similar dictionary maintained by the
  <ext-link ext-link-type="uri" xlink:href="http://www.umc-products.com">Uppsala
  Monitoring Centre</ext-link> for the
  <ext-link ext-link-type="uri" xlink:href="http://bioportal.bioontology.org/ontologies/WHO-ART">World
  Health Organisation Collaborating Centre for International Drug
  Monitoring</ext-link>. MedDRA and WHO-ART have a similar hierarchical
  structure consisting of System Organ Classes (SOC) and various
  grouping and descriptor terms.</p>
  <p>The MedDRA hierarchical structure consists of five levels: System
  Organ Class (SOC), High Level Group Terms (HLGT), High Level Terms
  (HLT), Preferred Terms (PT), and Lower Level Terms (LLT). The PT is a
  single medical description of a symptom or observation while the LLT
  is how a patient or data recorder would describe a symptom or
  observation. Each LLT belongs to one PT and, in general, data will be
  recorded at the LLT level but reported at the PT level (the adverse
  event). As of 2020 there are 27 SOCs and over 80,000 LLTs.</p>
  <p>The grouping of adverse events by SOC (or body-system) provides for
  possible relationships between the adverse events within a SOC. One
  consequence of this is the possibility that, for treatments which may
  affect a particular SOC, there may be raised rates for a number of
  adverse events within that SOC. A number of methods have recently been
  proposed to address the statistical issues in adverse event analysis
  by using these groupings of adverse events by body-system or SOC,
  taking into account the additional information provided by these
  relationships to increase the power of detecting real adverse event
  effects. These methods, which include both error controlling
  procedures for multiple hypothesis testing
  (<xref alt="Benjamini &amp; Hochberg, 1995" rid="ref-BH1995" ref-type="bibr">Benjamini
  &amp; Hochberg, 1995</xref>;
  <xref alt="Hu et al., 2010" rid="ref-HZZ2010" ref-type="bibr">Hu et
  al., 2010</xref>;
  <xref alt="Matthews, 2006" rid="ref-M2006" ref-type="bibr">Matthews,
  2006</xref>;
  <xref alt="Mehrotra &amp; Adewale, 2012" rid="ref-MA2012" ref-type="bibr">Mehrotra
  &amp; Adewale, 2012</xref>;
  <xref alt="Yekutieli, 2008" rid="ref-Y2008" ref-type="bibr">Yekutieli,
  2008</xref>), and Bayesian modelling approaches
  (<xref alt="Amy Xia et al., 2011" rid="ref-XMC2011" ref-type="bibr">Amy
  Xia et al., 2011</xref>;
  <xref alt="Berry &amp; Berry, 2004" rid="ref-BB2004" ref-type="bibr">Berry
  &amp; Berry, 2004</xref>;
  <xref alt="Carragher, 2017b" rid="ref-phdthesis" ref-type="bibr">Carragher,
  2017b</xref>), are implemented in the <monospace>R</monospace> package
  <monospace>c212</monospace> (Table
  <xref alt="1" rid="tableU003A1">1</xref>).</p>
  <table-wrap>
    <caption>
      <p>Methods in the c212 package.
      <styled-content id="tableU003A1"></styled-content></p>
    </caption>
    <table>
      <colgroup>
        <col width="59%" />
        <col width="41%" />
      </colgroup>
      <thead>
        <tr>
          <th>Method</th>
          <th>Description</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td>Benjamini-Hochberg procedure
          (<xref alt="Benjamini &amp; Hochberg, 1995" rid="ref-BH1995" ref-type="bibr">Benjamini
          &amp; Hochberg, 1995</xref>)</td>
          <td>Control of False Discovery Rate</td>
        </tr>
        <tr>
          <td>Group Benjamini-Hochberg procedure
          (<xref alt="Hu et al., 2010" rid="ref-HZZ2010" ref-type="bibr">Hu
          et al., 2010</xref>)</td>
          <td>Control of False Discovery Rate</td>
        </tr>
        <tr>
          <td>Double false discovery rate
          (<xref alt="Mehrotra &amp; Adewale, 2012" rid="ref-MA2012" ref-type="bibr">Mehrotra
          &amp; Adewale, 2012</xref>)</td>
          <td>Control of False Discovery Rate</td>
        </tr>
        <tr>
          <td>Subset BH-procedure
          (<xref alt="Yekutieli, 2008" rid="ref-Y2008" ref-type="bibr">Yekutieli,
          2008</xref>)</td>
          <td>Control of False Discovery Rate</td>
        </tr>
        <tr>
          <td>Bonferroni correction
          (<xref alt="Matthews, 2006" rid="ref-M2006" ref-type="bibr">Matthews,
          2006</xref>)</td>
          <td>Control of Familywise Error Rate</td>
        </tr>
        <tr>
          <td>Berry and Berry model
          (<xref alt="Berry &amp; Berry, 2004" rid="ref-BB2004" ref-type="bibr">Berry
          &amp; Berry, 2004</xref>)</td>
          <td>Bayesian model for end of trial data</td>
        </tr>
        <tr>
          <td>Berry and Berry model without point-mass
          (<xref alt="Amy Xia et al., 2011" rid="ref-XMC2011" ref-type="bibr">Amy
          Xia et al., 2011</xref>)</td>
          <td>Bayesian model for end of trial data</td>
        </tr>
        <tr>
          <td>Interim analysis model
          (<xref alt="Carragher, 2017b" rid="ref-phdthesis" ref-type="bibr">Carragher,
          2017b</xref>)</td>
          <td>Bayesian model for interim trial data</td>
        </tr>
        <tr>
          <td>Interim analysis model without point-mass
          (<xref alt="Carragher, 2017b" rid="ref-phdthesis" ref-type="bibr">Carragher,
          2017b</xref>)</td>
          <td>Bayesian model for interim trial data</td>
        </tr>
      </tbody>
    </table>
  </table-wrap>
</sec>
<sec id="statement-of-need">
  <title>Statement of Need</title>
  <p>The detection of safety issues in the post-marketing phase of a
  treatment’s life cycle, as opposed to the trial phase, can have a
  serious effect on the health of patients and also a financial impact
  both for the companies developing the treatments, and the regulatory
  bodies responsible for overseeing them.</p>
  <p>The <monospace>R</monospace> package <monospace>c212</monospace>
  provides a self-contained set of methods for clinical trial safety
  investigators, statisticians and researchers, to aid in the early
  detection of adverse events. It is designed to be easy to use with a
  simple data input format and interface.</p>
  <p>The primary use case for the software is in the statistical
  analysis of adverse event incidence and occurrence data during
  clinical trials. A second goal of the package is to provide reference
  implementations of the methods in Table
  <xref alt="1" rid="tableU003A1">1</xref> for use by researchers, both
  in the area of safety in clinical trials, as well those developing or
  testing methods for handling error rates when testing multiple
  hypotheses. Beyond safety in clinical trials, the package will be
  useful to any project which deals with multiple hypothesis testing, or
  projects where two groups of comparative data may be modelled by
  hierarchical Bayesian binomial or Poisson models, with recent
  extensions of the Bayesian models to observational data being
  developed
  (<xref alt="Carragher et al., 2020" rid="ref-RC2020" ref-type="bibr">Carragher
  et al., 2020</xref>).</p>
  <p>The <monospace>c212</monospace> package is currently being used
  both for clinical trial safety analysis
  (<xref alt="Fries et al., 2016" rid="ref-FKL2016" ref-type="bibr">Fries
  et al., 2016</xref>;
  <xref alt="Munsaka, 2018" rid="ref-Munsaka2018" ref-type="bibr">Munsaka,
  2018</xref>;
  <xref alt="Wang et al., 2018" rid="ref-WWM2018" ref-type="bibr">Wang
  et al., 2018</xref>) and as a research tool in the investigation and
  development of new safety methods
  (<xref alt="Tan et al., 2019" rid="ref-Tan2019" ref-type="bibr">Tan et
  al., 2019</xref>,
  <xref alt="2020" rid="ref-Tan2020" ref-type="bibr">2020</xref>). It
  has also been
  <ext-link ext-link-type="uri" xlink:href="https://visual-analytics.shinyapps.io/index/">implemented</ext-link>
  as part of an
  <ext-link ext-link-type="uri" xlink:href="https://community.amstat.org/biop/workinggroups/safety/safety-home">ASA
  Biopharm Safety Working Group</ext-link> workstream.</p>
</sec>
<sec id="overview">
  <title>Overview</title>
  <p>The Bayesian models, under assumptions of conditional independence,
  are fitted using a Gibbs sampling Markov Chain Monte-Carlo (MCMC)
  method
  (<xref alt="Robert &amp; Casella, 1999" rid="ref-RCR1999" ref-type="bibr">Robert
  &amp; Casella, 1999</xref>). The posterior distributions of the model
  parameters are used to assess which adverse events may have increased
  rates on the treatment arm. In the case of the Berry and Berry model,
  which is binomial, the <monospace>theta</monospace> model parameter,
  representing the increase in the log-odds of an event occurring on the
  treatment arm, is used for this purpose
  (<xref alt="Berry &amp; Berry, 2004" rid="ref-BB2004" ref-type="bibr">Berry
  &amp; Berry, 2004</xref>). For the interim analysis models, which are
  Poisson based, the increase in the log rate of an event on the
  treatment arm is used for adverse event assessment. As in the Berry
  and Berry model this is represented by the parameter
  <monospace>theta</monospace>
  (<xref alt="Carragher, 2017b" rid="ref-phdthesis" ref-type="bibr">Carragher,
  2017b</xref>). Functions for generating summary statistics and highest
  probability intervals are provided using the services of the
  <monospace>coda</monospace> package
  (<xref alt="Plummer et al., 2006" rid="ref-coda2006" ref-type="bibr">Plummer
  et al., 2006</xref>). The main convergence diagnostics available
  directly within the package are the Gelman-Rubin and Geweke statistics
  (<xref alt="Gelman et al., 2004" rid="ref-GCSR2004" ref-type="bibr">Gelman
  et al., 2004</xref>), again from the <monospace>coda</monospace>
  package. Access to the raw samples is available for further processing
  should that be required. The error controlling procedures included in
  the package follow exactly the method definitions in the papers which
  introduced them
  (<xref alt="Benjamini &amp; Hochberg, 1995" rid="ref-BH1995" ref-type="bibr">Benjamini
  &amp; Hochberg, 1995</xref>;
  <xref alt="Hu et al., 2010" rid="ref-HZZ2010" ref-type="bibr">Hu et
  al., 2010</xref>;
  <xref alt="Matthews, 2006" rid="ref-M2006" ref-type="bibr">Matthews,
  2006</xref>;
  <xref alt="Mehrotra &amp; Adewale, 2012" rid="ref-MA2012" ref-type="bibr">Mehrotra
  &amp; Adewale, 2012</xref>;
  <xref alt="Yekutieli, 2008" rid="ref-Y2008" ref-type="bibr">Yekutieli,
  2008</xref>). The following sections contain examples which cover the
  main uses of the software. The data sets and functions used are fully
  documented in the package.</p>
  <sec id="multiple-hypothesis-testing">
    <title>Multiple Hypothesis Testing</title>
    <p>The data set <monospace>c212.FDR.data</monospace> contains the
    results from a set of multiple hypothesis tests for adverse events
    grouped by body-system. The Group Benjamini-Hochberg procedure is
    applied to the data with control of the False Discovery Rate set at
    the 5% level. The <monospace>c212.err.cntrl</monospace> function,
    which provides the interface to the error controlling methods,
    returns the set of p-values/hypotheses deemed significant.</p>
    <code language="r script">library(c212)
data(c212.FDR.data, package=&quot;c212&quot;)
head(c212.FDR.data, 2)
B j AE p
1 Bdy-sys_5 7 Adv-Ev_24 1.000000
2 Bdy-sys_6 9 Adv-Ev_34 0.358949

p.sig &lt;- c212.err.cntrl(c212.FDR.data, method = &quot;GBH&quot;, alpha = 0.05)
print(p.sig)
          B j         AE        p p_weighted
1 Bdy-sys_3 6 Adv-Ev_911 0.000079   0.000000
2 Bdy-sys_3 3   Adv-Ev_8 0.000021   0.000000
3 Bdy-sys_3 1   Adv-Ev_6 0.000000   0.000000
4 Bdy-sys_3 5 Adv-Ev_910 0.000039   0.000000
5 Bdy-sys_3 2   Adv-Ev_7 0.000011   0.000000
6 Bdy-sys_3 4   Adv-Ev_9 0.010411   0.000000
7 Bdy-sys_3 7 Adv-Ev_912 0.003554   0.000000
8 Bdy-sys_2 1   Adv-Ev_2 0.005333   0.005333
9 Bdy-sys_2 2   Adv-Ev_3 0.016013   0.016013</code>
  </sec>
  <sec id="berry-and-berry-end-of-trial-analysis">
    <title>Berry and Berry End of Trial Analysis</title>
    <p>The data set <monospace>c212.trial.data</monospace> contains
    sample end of trial adverse event incidence counts. The data is
    modelled using the Berry and Berry model as follows:</p>
    <code language="r script">library(c212)
data(c212.trial.data, package=&quot;c212&quot;)
head(c212.trial.data, 2)
B j AE Group Count Total
1 Bdy-sys_2 1 Adv-Ev_2 1 20 450
2 Bdy-sys_2 4 Adv-Ev_5 2 21 450

mod.BB &lt;- c212.BB(c212.trial.data)</code>
    <p><monospace>mod.BB</monospace> contains the raw samples generated
    from the model fitting procedure. To perform a convergence
    check:</p>
    <code language="r script">conv.BB = c212.convergence.diag(mod.BB)
c212.print.convergence.summary(conv.BB)</code>
    <p>In order to assess which adverse events may be associated with
    treatment the function <monospace>c212.ptheta</monospace> is used.
    This calculates the posterior probability of an increase in log-odds
    of an event occurring on the treatment arm. A threshold may be used
    to view the adverse events which exceed some defined level, for
    example: 0.90:</p>
    <code language="r script">theta.pos_BB &lt;- c212.ptheta(mode.BB)

theta_pos.BB[theta_pos.BB$ptheta &gt; 0.9,]
B AE ptheta
2 Bdy-sys_2 Adv-Ev_2 0.9410417
6 Bdy-sys_3 Adv-Ev_6 1.0000000
7 Bdy-sys_3 Adv-Ev_7 1.0000000
8 Bdy-sys_3 Adv-Ev_8 1.0000000
9 Bdy-sys_3 Adv-Ev_9 0.9873500
10 Bdy-sys_3 Adv-Ev_910 0.9999333
11 Bdy-sys_3 Adv-Ev_911 0.9999917
12 Bdy-sys_3 Adv-Ev_912 0.9964917</code>
    <p>The high posterior probabilities may indicate a possible
    association with treatment for these adverse events.</p>
  </sec>
  <sec id="interim-analysis">
    <title>Interim Analysis</title>
    <p>Apart from the function used to fit the model, the procedure for
    fitting and accessing interim analysis data is exactly the same as
    for the Berry and Berry model.</p>
    <code language="r script">library(c212)
data(c212.trial.interval.data1)
head(c212.trial.interval.data1, 2)
Interval I_index         B       AE Group Count Exposure
0.0-180.0       0 Bdy-sys_1 Adv-Ev_1     1    87 160133.7
0.0-180.0       0 Bdy-sys_1 Adv-Ev_1     2   103 163224.6
mod.BB.interim &lt;- c212.BB.interim(c212.trial.interval.data1)</code>
  </sec>
</sec>
<sec id="software-details-and-availability">
  <title>Software Details and Availability</title>
  <p>The <monospace>c212</monospace> package was initially released to
  CRAN in 2017 and has been through a number of release cycles. Before
  each release a full set of unit and functional tests are performed on
  the package development system, including memory checks with valgrind
  (<xref alt="Seward &amp; Nethercote, 2005" rid="ref-valgrind" ref-type="bibr">Seward
  &amp; Nethercote, 2005</xref>) and Google address sanitizer
  (<xref alt="Serebryany et al., 2012" rid="ref-asan" ref-type="bibr">Serebryany
  et al., 2012</xref>). The package documentation also contains tests
  and examples based on data included in the package.</p>
  <p>The <monospace>c212</monospace> package is most easily downloaded
  and installed directly from CRAN
  (<xref alt="Carragher, 2017a" rid="ref-cran" ref-type="bibr">Carragher,
  2017a</xref>) or, alternatively, from the corresponding GitHub
  repository
  (<xref alt="Carragher, 2020" rid="ref-github" ref-type="bibr">Carragher,
  2020</xref>).</p>
  <p>The authors are interested in extending the software to include new
  methods, particularly in the area of safety analysis, and would
  welcome collaborations in this area. Any support issues or questions
  can be addressed directly to the corresponding author, through the
  associated CRAN maintainer email address, or through the Github
  repository.</p>
  <sec id="performance">
    <title>Performance</title>
    <p>The Bayesian models are expensive to fit in terms of both
    computation and memory. The main issue is the number of parameters
    in the model. For the Berry and Berry model with
    <inline-formula><alternatives>
    <tex-math><![CDATA[N]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula>
    adverse events, and <inline-formula><alternatives>
    <tex-math><![CDATA[B]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>B</mml:mi></mml:math></alternatives></inline-formula>
    SOCs there are <inline-formula><alternatives>
    <tex-math><![CDATA[(2 \times N + 5 \times B + 6)]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>5</mml:mn><mml:mo>×</mml:mo><mml:mi>B</mml:mi><mml:mo>+</mml:mo><mml:mn>6</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>
    parameters in total. With <inline-formula><alternatives>
    <tex-math><![CDATA[C]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>C</mml:mi></mml:math></alternatives></inline-formula>
    parallel MCMC chains and <inline-formula><alternatives>
    <tex-math><![CDATA[I]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>I</mml:mi></mml:math></alternatives></inline-formula>
    iterations of the MCMC sampler, this will require space for
    <inline-formula><alternatives>
    <tex-math><![CDATA[C \times I \times (2 \times N + 5 \times B + 6)]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>C</mml:mi><mml:mo>×</mml:mo><mml:mi>I</mml:mi><mml:mo>×</mml:mo><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>5</mml:mn><mml:mo>×</mml:mo><mml:mi>B</mml:mi><mml:mo>+</mml:mo><mml:mn>6</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
    double precision numbers to store the samples. For larger datasets,
    the calculation of the convergence diagnostics and summary
    statistics may be time consuming as the samples are passed to the
    <monospace>coda</monospace> package.</p>
    <p><bold>Example:</bold> A trial with 23 SOCs and 497 AEs, 5
    parallel chains and 40,000 iterations after burn-in, will require
    space for 133,800,000 doubles, equating to approximately 1GB of
    memory storage for the samples alone (assuming 8 bytes per
    double).</p>
    <p>It is recommended that at least twice the storage required for
    the samples be available for fitting any of the Bayesian models.</p>
  </sec>
</sec>
<sec id="acknowledgements">
  <title>Acknowledgements</title>
  <p>This work was funded by the Engineering and Physical Sciences
  Research Council (EPSRC) UK (award reference 1521741) and Frontier
  Science (Scotland) Ltd.</p>
</sec>
</body>
<back>
<ref-list>
  <ref-list>
    <ref id="ref-BH1995">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Benjamini</surname><given-names>Yoav</given-names></name>
          <name><surname>Hochberg</surname><given-names>Yosef</given-names></name>
        </person-group>
        <article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title>
        <source>Journal of the Royal Statistical Society. Series B (Methodological)</source>
        <year iso-8601-date="1995">1995</year>
        <volume>57</volume>
        <issue>1</issue>
        <issn>00359246</issn>
        <uri>http://www.jstor.org/stable/2346101</uri>
        <pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-HZZ2010">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Hu</surname><given-names>J. X.</given-names></name>
          <name><surname>Zhao</surname><given-names>H.</given-names></name>
          <name><surname>Zhou</surname><given-names>H. H.</given-names></name>
        </person-group>
        <article-title>False discovery rate control with groups</article-title>
        <source>Journal of the American Statistical Association</source>
        <year iso-8601-date="2010">2010</year>
        <volume>105</volume>
        <issue>491</issue>
        <issn>0162-1459 (Print)
        0162-1459 (Linking)</issn>
        <pub-id pub-id-type="doi">10.1198/jasa.2010.tm09329</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-MA2012">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Mehrotra</surname><given-names>D. V.</given-names></name>
          <name><surname>Adewale</surname><given-names>A. J.</given-names></name>
        </person-group>
        <article-title>Flagging clinical adverse experiences: Reducing false discoveries without materially compromising power for detecting true signals</article-title>
        <source>Statistics in Medicine</source>
        <year iso-8601-date="2012">2012</year>
        <volume>31</volume>
        <issue>18</issue>
        <issn>1097-0258 (Electronic)
        0277-6715 (Linking)</issn>
        <pub-id pub-id-type="doi">10.1002/sim.5310</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-Y2008">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Yekutieli</surname><given-names>Daniel</given-names></name>
        </person-group>
        <article-title>False discovery rate control for non-positively regression dependent test statistics</article-title>
        <source>Journal of Statistical Planning and Inference</source>
        <year iso-8601-date="2008">2008</year>
        <volume>138</volume>
        <issue>2</issue>
        <issn>0378-3758</issn>
        <uri>http://www.sciencedirect.com/science/article/pii/S0378375807002510</uri>
        <pub-id pub-id-type="doi">10.1016/j.jspi.2007.06.006</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-M2006">
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name><surname>Matthews</surname><given-names>John N. S.</given-names></name>
        </person-group>
        <source>Introduction to randomized controlled clinical trials, second edition</source>
        <publisher-name>Chapman &amp; Hall/CRC</publisher-name>
        <year iso-8601-date="2006">2006</year>
        <isbn>978-1-58488-624-2</isbn>
        <pub-id pub-id-type="doi">doi:10.1201/9781420011302.fmatt</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-BB2004">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Berry</surname><given-names>Scott M.</given-names></name>
          <name><surname>Berry</surname><given-names>Donald A.</given-names></name>
        </person-group>
        <article-title>Accounting for multiplicities in assessing drug safety: A three-level hierarchical mixture model</article-title>
        <source>Biometrics</source>
        <year iso-8601-date="2004">2004</year>
        <volume>60</volume>
        <issue>2</issue>
        <issn>1541-0420</issn>
        <uri>http://dx.doi.org/10.1111/j.0006-341X.2004.00186.x</uri>
        <pub-id pub-id-type="doi">10.1111/j.0006-341X.2004.00186.x</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-XMC2011">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Amy Xia</surname><given-names>H.</given-names></name>
          <name><surname>Ma</surname><given-names>Haijun</given-names></name>
          <name><surname>Carlin</surname><given-names>Bradley P.</given-names></name>
        </person-group>
        <article-title>Bayesian hierarchical modeling for detecting safety signals in clinical trials</article-title>
        <source>Journal of Biopharmaceutical Statistics</source>
        <year iso-8601-date="2011">2011</year>
        <volume>21</volume>
        <issue>5</issue>
        <issn>1054-3406</issn>
        <uri>http://dx.doi.org/10.1080/10543406.2010.520181</uri>
        <pub-id pub-id-type="doi">10.1080/10543406.2010.520181</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-phdthesis">
      <element-citation publication-type="thesis">
        <person-group person-group-type="author">
          <name><surname>Carragher</surname><given-names>Raymond</given-names></name>
        </person-group>
        <article-title>Detecting safety signals in randomised controlled trials</article-title>
        <publisher-name>University of Strathclyde</publisher-name>
        <year iso-8601-date="2017">2017</year>
      </element-citation>
    </ref>
    <ref id="ref-WWM2018">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Wang</surname><given-names>William</given-names></name>
          <name><surname>Whalen</surname><given-names>Ed</given-names></name>
          <name><surname>Munsaka</surname><given-names>Melvin</given-names></name>
          <name><surname>Li</surname><given-names>Judy</given-names></name>
          <name><surname>Fries</surname><given-names>Michael</given-names></name>
          <name><surname>Kracht</surname><given-names>Karolyn</given-names></name>
          <name><surname>Sanchez-Kam</surname><given-names>Matilde</given-names></name>
          <name><surname>Singh</surname><given-names>Krishan</given-names></name>
          <name><surname>Zhou</surname><given-names>Kefei</given-names></name>
        </person-group>
        <article-title>On quantitative methods for clinical safety monitoring in drug development</article-title>
        <source>Statistics in Biopharmaceutical Research</source>
        <publisher-name>Taylor &amp; Francis</publisher-name>
        <year iso-8601-date="2018">2018</year>
        <volume>10</volume>
        <issue>2</issue>
        <uri>https://doi.org/10.1080/19466315.2017.1409134</uri>
        <pub-id pub-id-type="doi">10.1080/19466315.2017.1409134</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-Munsaka2018">
      <element-citation publication-type="chapter">
        <person-group person-group-type="author">
          <name><surname>Munsaka</surname><given-names>Melvin S.</given-names></name>
        </person-group>
        <article-title>A question-based approach to the analysis of safety data</article-title>
        <source>Biopharmaceutical applied statistics symposium : Volume 2 biostatistical analysis of clinical trials</source>
        <person-group person-group-type="editor">
          <name><surname>Peace</surname><given-names>Karl E.</given-names></name>
          <name><surname>Chen</surname><given-names>Ding-Geng</given-names></name>
          <name><surname>Menon</surname><given-names>Sandeep</given-names></name>
        </person-group>
        <publisher-name>Springer Singapore</publisher-name>
        <publisher-loc>Singapore</publisher-loc>
        <year iso-8601-date="2018">2018</year>
        <isbn>978-981-10-7826-2</isbn>
        <uri>https://doi.org/10.1007/978-981-10-7826-2_11</uri>
        <pub-id pub-id-type="doi">10.1007/978-981-10-7826-2_11</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-FKL2016">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Fries</surname><given-names>M</given-names></name>
          <name><surname>Kracht</surname><given-names>K K</given-names></name>
          <name><surname>Li</surname><given-names>J</given-names></name>
          <name><surname>Munsaka</surname><given-names>M S</given-names></name>
          <name><surname>Sanchez-Kam</surname><given-names>M</given-names></name>
          <name><surname>Singh</surname><given-names>K P</given-names></name>
          <name><surname>Wang</surname><given-names>W</given-names></name>
          <name><surname>Whalen</surname><given-names>E</given-names></name>
          <name><surname>Zhou</surname><given-names>K.</given-names></name>
        </person-group>
        <article-title>Safety monitoring methodology in the premarketing setting</article-title>
        <source>JSM Proceedings, Biopharmaceutical Section</source>
        <publisher-name>Google Scholar</publisher-name>
        <year iso-8601-date="2016">2016</year>
        <uri>https://ww2.amstat.org/MembersOnly/proceedings/2016/data/assets/pdf/389675.pdf</uri>
      </element-citation>
    </ref>
    <ref id="ref-coda2006">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Plummer</surname><given-names>Martyn</given-names></name>
          <name><surname>Best</surname><given-names>Nicky</given-names></name>
          <name><surname>Cowles</surname><given-names>Kate</given-names></name>
          <name><surname>Vines</surname><given-names>Karen</given-names></name>
        </person-group>
        <article-title>CODA: Convergence diagnosis and output analysis for MCMC</article-title>
        <source>R News</source>
        <year iso-8601-date="2006">2006</year>
        <volume>6</volume>
        <issue>1</issue>
        <uri>http://CRAN.R-project.org/doc/Rnews/</uri>
      </element-citation>
    </ref>
    <ref id="ref-GCSR2004">
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name><surname>Gelman</surname><given-names>Andrew</given-names></name>
          <name><surname>Carlin</surname><given-names>John B.</given-names></name>
          <name><surname>Stern</surname><given-names>Hal S.</given-names></name>
          <name><surname>Rubin</surname><given-names>Donald B.</given-names></name>
        </person-group>
        <source>Bayesian Data Analysis</source>
        <publisher-name>Chapman &amp; Hall/CRC</publisher-name>
        <year iso-8601-date="2004">2004</year>
      </element-citation>
    </ref>
    <ref id="ref-RCR1999">
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name><surname>Robert</surname><given-names>Christian P.</given-names></name>
          <name><surname>Casella</surname><given-names>George</given-names></name>
        </person-group>
        <source>Monte Carlo statistical methods</source>
        <publisher-name>Springer New York</publisher-name>
        <year iso-8601-date="1999">1999</year>
      </element-citation>
    </ref>
    <ref id="ref-Tan2019">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Tan</surname><given-names>Xianming</given-names></name>
          <name><surname>Liu</surname><given-names>Guanghan F.</given-names></name>
          <name><surname>Zeng</surname><given-names>Donglin</given-names></name>
          <name><surname>Wang</surname><given-names>William</given-names></name>
          <name><surname>Diao</surname><given-names>Guoqing</given-names></name>
          <name><surname>Heyse</surname><given-names>Joseph F.</given-names></name>
          <name><surname>Ibrahim</surname><given-names>Joseph G.</given-names></name>
        </person-group>
        <article-title>Controlling false discovery proportion in identification of drug-related adverse events from multiple system organ classes</article-title>
        <source>Statistics in Medicine</source>
        <year iso-8601-date="2019">2019</year>
        <volume>38</volume>
        <issue>22</issue>
        <uri>https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.8304</uri>
        <pub-id pub-id-type="doi">10.1002/sim.8304</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-Tan2020">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Tan</surname><given-names>Xianming</given-names></name>
          <name><surname>Chen</surname><given-names>Bingshu E.</given-names></name>
          <name><surname>Sun</surname><given-names>Jianping</given-names></name>
          <name><surname>Patel</surname><given-names>Tejendra</given-names></name>
          <name><surname>Ibrahim</surname><given-names>Joseph G.</given-names></name>
        </person-group>
        <article-title>A hierarchical testing approach for detecting safety signals in clinical trials</article-title>
        <source>Statistics in Medicine</source>
        <year iso-8601-date="2020">2020</year>
        <volume>39</volume>
        <issue>10</issue>
        <uri>https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.8495</uri>
        <pub-id pub-id-type="doi">10.1002/sim.8495</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-RC2020">
      <element-citation publication-type="article-journal">
        <person-group person-group-type="author">
          <name><surname>Carragher</surname><given-names>Raymond</given-names></name>
          <name><surname>Mueller</surname><given-names>Tanja</given-names></name>
          <name><surname>Bennie</surname><given-names>Marion</given-names></name>
          <name><surname>Robertson</surname><given-names>Chris</given-names></name>
        </person-group>
        <article-title>A Bayesian hierarchical approach for multiple outcomes in routinely collected healthcare data</article-title>
        <source>Statistics in Medicine</source>
        <year iso-8601-date="2020">2020</year>
        <volume>39</volume>
        <uri>https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.8563</uri>
        <pub-id pub-id-type="doi">10.1002/sim.8563</pub-id>
      </element-citation>
    </ref>
    <ref id="ref-github">
      <element-citation>
        <person-group person-group-type="author">
          <name><surname>Carragher</surname><given-names>Raymond</given-names></name>
        </person-group>
        <article-title>c212: Methods for detecting safety signals in clinical trials using body-systems (system organ classes)</article-title>
        <source>​GitHub repository</source>
        <publisher-name>​GitHub</publisher-name>
        <year iso-8601-date="2020">2020</year>
        <uri>https://github.com/rcarragh/c212</uri>
      </element-citation>
    </ref>
    <ref id="ref-cran">
      <element-citation>
        <person-group person-group-type="author">
          <name><surname>Carragher</surname><given-names>Raymond</given-names></name>
        </person-group>
        <article-title>c212: Methods for detecting safety signals in clinical trials using body-systems (system organ classes)</article-title>
        <source>​CRAN repository</source>
        <publisher-name>​CRAN</publisher-name>
        <year iso-8601-date="2017">2017</year>
        <uri> https://CRAN.R-project.org/package=c212</uri>
      </element-citation>
    </ref>
    <ref id="ref-valgrind">
      <element-citation publication-type="paper-conference">
        <person-group person-group-type="author">
          <name><surname>Seward</surname><given-names>Julian</given-names></name>
          <name><surname>Nethercote</surname><given-names>Nicholas</given-names></name>
        </person-group>
        <article-title>Using valgrind to detect undefined value errors with bit-precision</article-title>
        <source>Proceedings of the annual conference on USENIX annual technical conference</source>
        <publisher-name>USENIX Association</publisher-name>
        <publisher-loc>USA</publisher-loc>
        <year iso-8601-date="2005">2005</year>
      </element-citation>
    </ref>
    <ref id="ref-asan">
      <element-citation publication-type="paper-conference">
        <person-group person-group-type="author">
          <name><surname>Serebryany</surname><given-names>Konstantin</given-names></name>
          <name><surname>Bruening</surname><given-names>Derek</given-names></name>
          <name><surname>Potapenko</surname><given-names>Alexander</given-names></name>
          <name><surname>Vyukov</surname><given-names>Dmitry</given-names></name>
        </person-group>
        <article-title>AddressSanitizer: A fast address sanity checker</article-title>
        <source>Proceedings of the 2012 USENIX conference on annual technical conference</source>
        <publisher-name>USENIX Association</publisher-name>
        <publisher-loc>USA</publisher-loc>
        <year iso-8601-date="2012">2012</year>
      </element-citation>
    </ref>
  </ref-list>
</ref-list>
</back>
</article>
